Recognition molecules (RM), especially antibodies (A) that bind specifically to the Core-1 (C1) antigen, comprising defined amino acids sequences (1-6) given in the specification and below, are new. Recognition molecules (RM), especially antibodies (A) that bind specifically to the Core-1 (C1) antigen, comprising defined amino acids sequences (1-6): (a) AsnTyrTrpLeuGly (1); (b) AspIleTyrPro(Gly) 3TyrThrAsnTyrAsnGluLysPheLysGly (2); (c) AspIleTyrPro(Gly) 2SerTyrThrAsnTyrAsnGluLysPheLysGly (3); (d) TyrAspAlaAlaGlyProTrpPheAlaTyr (4); (e) TyrAspAlaAlaGlyProGlyPheAlaTyr (5); or (f) TyrAspAsnHisTyrPheAspTyr (6). Independent claims are also included for: (1) construct (B) consisting of (A) fused, chemically coupled or non-covalently associated with additional sequences and/or structures; (2) isolated nucleic acid (NA) containing sequences that encode at least one (A) or (B); (3) expression cassette or vector (X) comprising NA and functionally linked promoter; (4) virus or host cell that contains at least one (X); (5) organism that contains at least one host cell of (4); (6) method for preparing (A); and (7) kit containing (A) and/or (B). ACTIVITY : Cytostatic. A multibody (104; sequence of about 200 amino acids reproduced) was coupled to a chelating group then loaded with yttrium99. It was injected (dose 100 MicroCi) into the tail vein of a mouse, subcutaneously implanted with ZA-75-1 (Core-1 positive) tumor cells. A second dose was given after 3 weeks and this treatment produced a significant reduction in tumor growth (no figures given). MECHANISM OF ACTION : Neutralization of Core-1 antigen; Vaccine.